Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Trial of Lamivudine Plus Interferon Versus Lamivudine for the Treatment of HBeAg Positive Chronic Hepatitis B Virus (HBV)

NCT00140725 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00140725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00140725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Trial of Lamivudine Plus Interferon Versus Lamivudine for the Treatment of HBeAg Positive Chronic Hepatitis B Virus (HBV)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2000
Completion date
Not reported
Enrollment
160
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b